Articles by Noopur Raje, MD
Dr. Raje shared findings on CAR T-cell therapy in earlier lines of treatment for relapsed or refractory multiple myeloma.
Dr. Raje discussed the Perseus trial, in which most patients were progression-free at four years after a four-drug regimen.
The panel talks about the future of CAR-T: more targets, sequencing, and other patient considerations.
The panel considers where CAR T-cell therapy should fit in the myeloma treatment paradigm.
The panel compares clinical trial and real-world data for CAR-Ts.
The panel discusses treatment-related side effects such as CRS, ICANS, and more.
Drs. Raje and Patel discuss how they decide between CAR-T and bispecifics for their myeloma patients.
The panel discusses which patients may not be suitable for CAR T-cell therapy.
The panel discussed how CAR-T impacts myeloma standard of care.
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
Noopur Raje, MD, says the future of BCMA-directed CAR T-cell therapies may lie with next-generation agents such as bb21217.
Noopur Raje, MD, discusses the safety and efficacy results of the CRB-402 trial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.